Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.

Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and ...

Stoke Therapeutics, Inc. (STOK) shares soared 9.4% in the last trading session to close at $12.60. The move was backed by solid volume with far more shares changing hands than in a normal session.

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Wedbush dropped their Q1 2025 earnings estimates for shares of Stoke Therapeutics in a report released on Wednesday, February 19th.

Following the case at Stoke-on-Trent Crown Court, council deputy leader Amjid Wazir said: "The work carried out by our trading standards team sends a clear message — illegal tobacco sales will ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...

As per the agreement, Stoke will retain development and commercialization ... including banks, brokerages, trading platforms and financial exchanges.

CEO of Stoke Therapeutics. Price Action: At last check Tuesday, BIIB was down 0.79% at $136.24, and STOK was down 3.15% at $10.34. Up Next: Transform your trading with Benzinga Edge's one-of-a ...

Trading standards investigators and police have welcomed the prosecution of a shopkeeper in a crackdown on the sale of dodgy fags and tobacco. Ismail Muhammed ran Waterloo Stores, in Burslem. But the ...